For laboratory research use only. Not for human consumption. All compounds referenced in this article are sold by Explicit SARMs solely as reference materials for in-vitro and animal research by qualified professionals. Nothing here is medical advice, and no statement has been evaluated by the FDA. These materials are not intended to diagnose, treat, cure or prevent any disease.
BPC-157 and TB-500 are usually sold side by side, and often in the same vial, so they tend to be discussed as if they were one thing. They are not. They have different origins, proposed mechanisms and research histories, and the quality of evidence behind each is uneven. This overview sets out what each peptide is, what kinds of research have been published, and where the gaps are.
Explicit SARMs supplies BPC-157, TB-500 and the combined BPC-157 / TB-500 Blend strictly as laboratory reference material.
Two Different Peptides
- BPC-157: a synthetic 15-amino-acid peptide whose sequence is a partial fragment of a protein originally isolated from gastric juice (“body protection compound”).
- TB-500: a synthetic peptide based on the actin-binding region of thymosin beta-4, a naturally occurring 43-amino-acid protein.
- Regulatory status: neither is approved by the FDA or any other regulator for any indication.
BPC-157: What Has Been Studied
Most of the BPC-157 literature consists of rodent and cell-culture studies. These have examined models of gastrointestinal, tendon, ligament, muscle and vascular injury, and the proposed mechanisms involve angiogenesis, nitric oxide signaling and growth-factor pathways. The body of work is large, but a large share of it comes from one research group. Independent replication and controlled human data are limited. Any reading of the literature should treat mechanism claims as hypotheses, not established pharmacology.
TB-500 and Thymosin Beta-4: What Has Been Studied
Thymosin beta-4 is one of the main proteins cells use to sequester actin monomers, which links it to cell migration, wound-healing models and blood-vessel formation in preclinical work. Much of the published research concerns the full-length protein. Because TB-500 is a fragment, results for thymosin beta-4 cannot be assumed to carry over to TB-500 without direct evidence. That distinction is easy to lose in catalog copy and worth preserving in study design.
Why Researchers Pair Them
The rationale for pairing is that the two peptides are proposed to work through different pathways, one associated with angiogenic and growth-factor signaling and the other with actin dynamics and cell motility. That makes the combination an obvious question for tissue-repair models. It is a question, not an answer, though. Published data on the combination are sparse compared with either peptide alone. For more on the fixed-ratio product, see our BPC-157 / TB-500 blend FAQ.
Where the Evidence Stops
- Most findings come from animal models, and translation to any other setting has not been demonstrated.
- For BPC-157, replication outside the originating group is limited.
- For TB-500, much of the cited evidence is actually for full-length thymosin beta-4.
- Both peptides appear on the World Anti-Doping Agency’s prohibited list (BPC-157 under S0, non-approved substances; TB-500 under S2, peptide hormones, growth factors and related substances), which matters for any work involving sport-related analytical testing.
Design and Documentation Notes
If the goal is to attribute an effect, run single-peptide arms alongside any blend arm. A fixed 1:1 blend such as the 20mg blend (10 mg of each peptide) is convenient, but it can’t separate the contributions of the two components. Record the lot number, reconstitution solvent and date for every vial. A certificate of analysis is available on request through our contact page, and our products are purity-tested by an independent third-party lab. For a blend, confirm that the COA identifies both peptides.
Frequently Asked Questions
Are BPC-157 and TB-500 the same thing?
No. They are unrelated peptides with different sequences, origins and proposed mechanisms.
Is TB-500 the same as thymosin beta-4?
No. TB-500 is a synthetic fragment based on part of thymosin beta-4, and thymosin beta-4 is the full-length protein.
Are these peptides approved for human use?
No. Both are sold strictly for laboratory research, and we do not provide dosing, administration or usage guidance.